What Is Cagrilintide?

Also known as: Amylin analog, CagriSema component

Cagrilintide is a long-acting analog of amylin, the hormone co-released with insulin that tells the brain a meal is filling. Novo Nordisk developed it as the partner molecule in CagriSema (cagrilintide + semaglutide), which posted ~23% weight loss in phase 3.

Its appeal is mechanistic: amylin signaling is a completely separate satiety channel from GLP-1, so stacking the two adds effect rather than overlapping. Solo, cagrilintide produced ~10-12% weight loss in trials — meaningful on its own.

What is Cagrilintide studied for?

Side effects & safety

Trial profile: nausea and GI effects similar to GLP-1s but often described as milder; injection-site reactions. Combined with a GLP-1, GI effects compound — which is why titration discipline matters most in stacks.

Legal & approval status

Investigational; unapproved solo. Circulates as a research chemical in the gray market.

Typical dosing at a glance

Commonly reported protocols use 250 mcg–2.4 mg, 1x weekly, via subcutaneous injection. For the mixing math — how much bacteriostatic water, exact syringe units, doses per vial — see the Cagrilintide reconstitution calculator →

Related peptides

What is Semaglutide?What is Tirzepatide?What is Retatrutide?What is AOD-9604?What is HGH Fragment 176-191?

Educational overview based on published research and commonly reported community protocols — not medical advice, and not an endorsement of any compound. Consult a licensed healthcare provider.